An inducible caspase 9 safety switch for T-cell therapy

Karin C. Straathof, Martin A. Pulè, Patricia Yotnda, Gianpietro Dotti, Elio F. Vanin, Malcolm K. Brenner, Helen E. Heslop, David M. Spencer, Cliona M. Rooney

Research output: Contribution to journalArticlepeer-review

492 Scopus citations


The efficacy of adoptive T-cell therapy as treatment for malignancies may be enhanced by genetic modification of infused cells. However, oncogenic events due to vector/transgene integration, and toxicities due to the infused cells themselves, have tempered enthusiasm. A safe and efficient means of removing aberrant cells in vivo would ameliorate these concerns. We describe a "safety switch" that can be stably and efficiently expressed in human T cells without impairing phenotype, function, or antigen specificity. This reagent is based on a modified human caspase 9 fused to a human FK506 binding protein (FKBP) to allow conditional dimerization using a small molecule pharmaceutical. A single 10-nM dose of synthetic dimerizer drug induces apoptosis in 99% of transduced cells selected for high transgene expression in vitro and in vivo. This system has several advantages over currently available suicide genes. First, it consists of human gene products with low potential immunogenicity. Second, administration of dimerizer drug has no effects other than the selective elimination of transduced T cells. Third, inducible caspase 9 maintains function in T cells overexpressing antiapoptotic molecules. These characteristics favor incorporation of inducible caspase 9 as a safety feature in human T-cell therapies.

Original languageEnglish (US)
Pages (from-to)4247-4254
Number of pages8
Issue number11
StatePublished - Jun 1 2005

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'An inducible caspase 9 safety switch for T-cell therapy'. Together they form a unique fingerprint.

Cite this